The average of price targets set by Wall Street analysts indicates a potential upside of 59.5% in Omada Health, Inc. (OMDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omada Health's digital healthcare platform helps patients between doctors visits, improving outcomes. A growing trove of data shows the company's success in improving its members' health -- especially those on GLP-1s.
Nutex Health (NASDAQ: NUTX - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends. Institutional and Insider Ownership 5.3% of Nutex
Omada Health targets enterprise GLP-1 companion care, leveraging its platform to manage high employer demand for GLP-1 drugs. 2025 revenues grew 53% to $260M; 2026 guidance implies 22% topline growth and $7–15M adjusted EBITDA. OMDA now prescribes GLP-1s, aiming to differentiate via integrated clinical, behavioral, and benefit design solutions for employers.
Omada Health, Inc. (OMDA) Q4 2025 Earnings Call Transcript
The headline numbers for Omada Health, Inc. (OMDA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support employers looking to increase access to GLP-1 medications for obesity, including clinical evaluation, prescribing, and ongoing medical guidance and oversight. Members purchase their medications independently through cash-pay channels, helping employers limit their direct exposure to medication costs.
Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year Highlights Highlights are for the fourth quarter and full year 2025, except where otherwise noted.
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,1 yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level (
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday, March 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.
Omada Health, Inc. (OMDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis , findings underscore the program's role in helping employers manage the complexity of today's weight loss medication market while delivering measurable, long-term value.1 The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,1 compared to 11.9% weight loss seen in real world evidence.2 Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,1 compared to published real world evidence.2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss1 – nearly twice the amount observed in the real world analysis.2 “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits.
Cigna Investments Inc. New purchased a new position in Omada Health, Inc. (NASDAQ: OMDA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,444,630 shares of the company's stock, valued at approximately $76,161,000. Omada Health comprises about
Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) President Wei-Li Shao sold 5,618 shares of the firm's stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the transaction, the president owned 69,079 shares in the company,
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk. Earnings and Valuation This table compares Establishment Labs
SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, including a presentation on Wednesday, Jan. 14, at 9 a.m.
Federated Hermes Inc. bought a new stake in Omada Health, Inc. (NASDAQ: OMDA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 500,000 shares of the company's stock, valued at approximately $9,150,000. Federated Hermes Inc. owned 1.94% of Omada Health
Omada Health remains a 'Buy' as Q3 results validated strong growth, with revenue up 50% y/y to $68 million and membership reaching 831,000. OMDA's new GLP-1 prescribing capability deepens client integration, enhances ROI, and strengthens competitive positioning in a complex medication landscape. Multi-condition adoption accelerated, with ~75% of new customers using multiple programs, driving operating leverage and reducing client churn risk for OMDA.
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events . A replay will also be available at the same link following the event.